US Startup Offers Genetic IQ Screening for Embryos, Sparking Ethical Debate

Heliospect Genomics markets controversial service allowing wealthy couples to select embryos based on predicted intelligence and other traits.

Heliospect Genomics charges up to $50,000 to screen 100 embryos for traits like IQ, height, and health risks.
The service has been used by more than a dozen couples, with some embryos selected for higher predicted IQ.
Critics argue the practice raises ethical concerns, potentially reinforcing ideas of 'superior' genetics.
The company uses UK Biobank data for its predictions, though its commercial intentions were not initially disclosed.
UK laws prohibit such selection, but it remains legal in the US, where regulation is less stringent.